A blockbuster launch, priced for perfection
- BRINSUPRI hit blockbuster status with over $1 billion in cumulative revenue in its first four quarters.
- Product revenue in Q3 2026 reached $524.4 million, with BRINSUPRI driving $400.1 million of the total.
- The FDA granted Priority Review for the ARIKAYCE label expansion with a target decision date in January 2027.
- The bear case centers on valuation, as the stock needs a flawless BRINSUPRI launch and positive TPIP data to support its price.
- TPIP peak sales expectations remain over $6 billion as Phase 3 enrollment advances in multiple conditions.
The launch changes the story
Insmed transitioned from a single-product biotech to a high-growth commercial company following the US launch of BRINSUPRI in August 2025. In the third quarter of 2026, BRINSUPRI revenue hit $400.1 million, bringing its cumulative first-year sales above the $1 billion mark. ARIKAYCE, the older inhaled antibiotic for MAC lung disease, brought in $124.4 million.
The bull case is driven by incredible early adoption and international expansion. BRINSUPRI launched in Japan in October 2026, creating a strong near-term growth vector. Management aims to drive even more sales by targeting patients with comorbid COPD and asthma. TPIP peak sales expectations sit above $6 billion after strong long-term data in pulmonary arterial hypertension.
ARIKAYCE also matters deeply to the growth profile. In September 2026, the FDA granted Priority Review for an application to expand the drug's label. If approved by the January 28, 2027 target date, ARIKAYCE could reach newly diagnosed MAC lung disease patients, a much larger group than its current narrow label allows.
The bear case centers on execution and price. Finn's valuation score is low, which means the market expects flawless performance. Any slowdown in BRINSUPRI sales or failure to expand into COPD and asthma populations would damage the growth narrative. Growth outside bronchiectasis depends heavily on TPIP and the core respiratory pipeline.
Two lung drugs pay the bills
Insmed makes money by selling prescription drugs through specialty pharmacies and distributors. All current product revenue comes from the Respiratory area, specifically through BRINSUPRI and ARIKAYCE.
BRINSUPRI is the growth engine. It is a once-daily oral drug for bronchiectasis, a long-term lung disease where damaged airways lead to flare-ups and infection risk. Its edge is being first to market for that use, plus the massive size of the untreated need.
ARIKAYCE is the established product. It is an inhaled antibiotic for MAC lung disease, a hard-to-treat lung infection. Insmed's proprietary Pulmovance delivery technology helps deliver the drug directly to the lungs.
The model can break in simple ways. Payers may tighten access, doctors may slow new starts, patients may stop therapy, or contract manufacturers may fail to supply enough product. Insmed also still spends heavily on research and sales, so the path to steady profit relies on keeping BRINSUPRI growth strong.
What Insmed is selling and testing
BRINSUPRI
An oral, once-daily drug for bronchiectasis. It launched in the US in Q3 2025 and Japan in Q4 2026.
ARIKAYCE
An inhaled antibiotic for adult MAC lung disease. The FDA set a January 28, 2027 action date for a major label expansion.
TPIP
An inhaled treprostinil prodrug being tested in pulmonary diseases. Management sees a $6 billion peak sales opportunity following positive open-label data.
INS1148
A Phase 2-ready antibody targeting interstitial lung disease. Insmed acquired the rights to develop it in late 2025.
Gene therapy programs
Early gene therapy programs targeting Duchenne muscular dystrophy and ALS. Both remain in Phase 1 trials.
Stopped brensocatib expansions
Insmed stopped brensocatib work in CRSsNP and HS after failed Phase 2b studies. That narrows the growth story outside bronchiectasis.
Revenue is entirely BRINSUPRI-led
The mix is for the three months ended September 30, 2026. Product revenue was split between BRINSUPRI at 76.3 percent and ARIKAYCE at 23.7 percent.
What could go wrong
BRINSUPRI launch slows down
High impact · Medium oddsNew drugs often get a massive first wave from patients who were waiting for treatment. The key question is whether BRINSUPRI can maintain its momentum organically. Any stumble in the asthma and COPD expansion effort would reset valuation expectations.
ARIKAYCE loses focus
Medium impact · Medium oddsThe internal thesis notes that ARIKAYCE growth could stall if the sales team and doctors shift too much attention to BRINSUPRI. The planned label expansion could offset this, but only if the regulatory review succeeds.
TPIP data disappoints
High impact · Medium oddsManagement set a $6 billion peak sales target for TPIP, which assumes successful Phase 3 outcomes and breaking existing orphan drug exclusivity. If trials are weak or delayed, the valuation gets harder to defend.
Regulators or payers push back
High impact · Medium oddsInsmed needs regulators to accept wider use of ARIKAYCE and needs payers to keep covering BRINSUPRI without tight restrictions. Insurers could add paperwork, deny claims, or force patients to try other drugs first.
Outside manufacturers stumble
Medium impact · Low oddsInsmed does not own its own manufacturing sites and relies entirely on contract manufacturers. A quality issue or supply delay could hurt both commercial sales and clinical trials.
Executive transition risk
Low impact · High oddsThe impending departure of the Chief Financial Officer introduces minor executive transition risk. A new financial leader could alter capital allocation or spending priorities.
In one breath
What does Insmed do?
Insmed develops and sells medicines for serious lung diseases and rare diseases. Its main products are BRINSUPRI for bronchiectasis and ARIKAYCE for MAC lung disease.
Why is BRINSUPRI important to INSM stock?
BRINSUPRI is Insmed's biggest product by revenue, generating $400.1 million in Q3 2026 alone. Management expects it to generate over $7 billion in peak sales.
What is the next big catalyst for Insmed?
The next items to watch are the FDA's decision on the ARIKAYCE expansion in January 2027 and ongoing BRINSUPRI launch metrics in Japan.
Why is Finn cautious on valuation?
Insmed has massive growth potential, but the market price appears to assume near-perfect execution. The stock needs BRINSUPRI to keep exploding and TPIP to deliver.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 15, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Insmed Incorporated in Finn's Biotechnology industry ranking.

